Akimbo Bio

Akimbo Bio is an early-stage biotechnology company developing next-generation in vivo lentiviral vector technology for cell therapy.

Its lead platform carries a dual CAR/TCR payload designed for direct in vivo delivery, with an initial focus on ovarian cancer.

The technology uses intelligent receptor crosstalk, in which TCR signalling modulates CAR activity to improve both safety and therapeutic precision, dampening responses to healthy tissue while enhancing activity against tumour-specific targets.